Evidence map›Paper›PMID 21619691›Full record

ReviewOrphanet journal of rare diseases2011

Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics.

Nathaniel Robb Whaley, Shinsuke Fujioka, Zbigniew K Wszolek

Open access · goldAbstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.

  1. Treatment for dysphagia (swallowing difficulties) in hereditary ataxia.The Cochrane database of systematic reviews · 2015
    Pooled it
  2. Time is brain: an expanded concept, not only for ischemic stroke A viewpoint of the Italian Association for Emergency Neurology (ANEU).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Syndromic Retinitis Pigmentosa: A Narrative Review.Vision (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Subcortical Cognition: The Fruit Below the Rind.Annual review of neuroscience · 2022
    Review
  11. An interactive analysis of the mouse oviductal miRNA profiles.Frontiers in cell and developmental biology · 2022
    Article
  12. Review
  13. Review
  14. Article
  15. Frequency of spinocerebellar ataxia mutations in patients with multiple system atrophy.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2021
    Article
  16. Article
  17. Chromosomal Deletion in 7q31.2-31.32 InvolvingBrain & NeuroRehabilitation · 2020
    Article
  18. Article
  19. Genetically modified rodent models of SCA17.Journal of neuroscience research · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nathaniel Robb WhaleyTri State Mountain Neurology, 105 Woodlawn Dr, Johnson City, TN 27604, USA.
Shinsuke Fujioka
Zbigniew K Wszolek
Mayo Clinic in Florida · US

Funding

Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
PD iPS Cell Line Research ConsortiumRC2NS070276 · NINDS · MCLEAN HOSPITAL · PI ISACSON, OLE · 2009 to 2010
$3.8M
Biomarkers for Preclinical Parkinson's diseaseR01NS057567 · NINDS · UNIVERSITY OF WASHINGTON · PI ZHANG, JING · 2008 to 2012
$3.1M
NINDS NIH HHS 1RC2 NS070276NINDS NIH HHS P50 NS 072187NINDS NIH HHS R01 NS057567
6 · The paper itself

Abstract

Type I autosomal dominant cerebellar ataxia (ADCA) is a type of spinocerebellar ataxia (SCA) characterized by ataxia with other neurological signs, including oculomotor disturbances, cognitive deficits, pyramidal and extrapyramidal dysfunction, bulbar, spinal and peripheral nervous system involvement. The global prevalence of this disease is not known. The most common type I ADCA is SCA3 followed by SCA2, SCA1, and SCA8, in descending order. Founder effects no doubt contribute to the variable prevalence between populations. Onset is usually in adulthood but cases of presentation in childhood have been reported. Clinical features vary depending on the SCA subtype but by definition include ataxia associated with other neurological manifestations. The clinical spectrum ranges from pure cerebellar signs to constellations including spinal cord and peripheral nerve disease, cognitive impairment, cerebellar or supranuclear ophthalmologic signs, psychiatric problems, and seizures. Cerebellar ataxia can affect virtually any body part causing movement abnormalities. Gait, truncal, and limb ataxia are often the most obvious cerebellar findings though nystagmus, saccadic abnormalities, and dysarthria are usually associated. To date, 21 subtypes have been identified: SCA1-SCA4, SCA8, SCA10, SCA12-SCA14, SCA15/16, SCA17-SCA23, SCA25, SCA27, SCA28 and dentatorubral pallidoluysian atrophy (DRPLA). Type I ADCA can be further divided based on the proposed pathogenetic mechanism into 3 subclasses: subclass 1 includes type I ADCA caused by CAG repeat expansions such as SCA1-SCA3, SCA17, and DRPLA, subclass 2 includes trinucleotide repeat expansions that fall outside of the protein-coding regions of the disease gene including SCA8, SCA10 and SCA12. Subclass 3 contains disorders caused by specific gene deletions, missense mutation, and nonsense mutation and includes SCA13, SCA14, SCA15/16, SCA27 and SCA28. Diagnosis is based on clinical history, physical examination, genetic molecular testing, and exclusion of other diseases. Differential diagnosis is broad and includes secondary ataxias caused by drug or toxic effects, nutritional deficiencies, endocrinopathies, infections and post-infection states, structural abnormalities, paraneoplastic conditions and certain neurodegenerative disorders. Given the autosomal dominant pattern of inheritance, genetic counseling is essential and best performed in specialized genetic clinics. There are currently no known effective treatments to modify disease progression. Care is therefore supportive. Occupational and physical therapy for gait dysfunction and speech therapy for dysarthria is essential. Prognosis is variable depending on the type of ADCA and even among kindreds.

Indexed as

GenotypeHumansPhenotypeSpinocerebellar AtaxiasSpinocerebellar Degenerations

Identifiers

PMID21619691
PMCPMC3123548
OpenAlexW2097800106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.